

# Correlation Between Cervical Lymph Nodes Metastases And Histological Types Of Nasopharyngeal Carcinoma

Ali Obaid Muthanna

E.N.T. Department, Faculty of Medicine & Health Sciences, Sana'a

## Abstract

*Objective: The aim is to investigate the relationship between cervical lymph nodes metastases and histological types of nasopharyngeal carcinoma. Methods: Prospective study conducted on 100 patients who had been diagnosed as nasopharyngeal carcinoma, in Otolaryngology department at AL-Thawra Teaching Hospital during the period from September 2003-January 2006. Results: Males 70% and females 30%. The mean age was 36.8 years. WHO type III was the most common type comprising 58% and presented with cervical Lymph nodes in 82.7%. WHO type I occurred in 30% and cervical lymph nodes metastases was 26.6%. WHO type II found in 12% and cervical lymph nodes were involved in 50%. Conclusion: Nasopharyngeal carcinoma affects males more than females Undifferentiated. nasopharyngeal carcinoma (WHO type III) was the most common type found in the nasopharynx followed by the keratinized (WHO type I) nasopharyngeal carcinoma. Cervical lymph node metastases occurred in high prevalence with undifferentiated nasopharyngeal carcinoma followed by the non keratinizing nasopharyngeal carcinoma (WHO type II).*

**Key words:** nasopharyngeal carcinoma, metastases cervical lymph nodes, WHO type.

## Introduction:

carcinoma (NPC) is low, but it varies significantly among ethnic groups and geographical regions. 1.2 NPC has an early tendency to locally spread and nodal involvement is highly frequent and bulky regardless of the size of the primary. 3.4

NPC can be difficult to diagnose. not only because is the post nasal space (PNS) is inaccessible to examination, but also it is frequently occupied by normal lympho-epithelium which can make differentiation from NPC difficult. Together with its frequent atypical presentation, it is not surprising that the diagnosis is missed or delayed. 5.6.7

Endemic NPC is biologically different from squamous cell carcinoma of the head and neck. Systemic relapse,

especially in those who present with locally advanced disease, is more commonly seen and tends to be more aggressive. 8.9 Most NPC in endemic areas are of the World Health Organization (WHO) type II (non keratinizing carcinoma) and type III undifferentiated carcinoma. (WHO type III). 10

NPC has unique features among head and neck malignancies that increase the significance of quality of life. 11 NPC affects a younger group of patients than do other carcinomas of the head and neck, and usually is not associated with smoking or alcohol abuse. 11-15

The purpose of this study is to investigate the correlation between cervical lymph nodes involvement and histological types of nasopharyngeal carcinoma.

**Methods:**

One hundred cases had of nasopharyngeal carcinoma are included in this study. All patients underwent history, clinical, examination, nasal endoscopy, biopsy from the nasopharynx under local anesthesia, fine needle aspiration biopsy (FNAB) and histopathological examination. They were attended to in Oto Rhino-Laryngology Department, at Al-Thawra Teaching Hospital, Sana'a, Yemen, during the period September 2003 – January 2006.

**Results:**

100 patients diagnosed as nasopharyngeal carcinoma were investigated during the study period from September 2003 to January 2006. males 70 (70%) female 30 (30%) with mean age 36.8 years. According to WHO histological types were: WHO type III 42 (72.4%) males, 16 (27.6%) females, WHO type II 8 (66.7%) male, 4 (33.3%) females, WHO type I 20 (66.7%) and 10 (33.3%) females Table 1.

Cervical lymph nodes involvement found in 62 (62%) 38% unilateral and 24% bilateral in NPC.

Histological types of (WHO III) 58 (58%), keratinized (WHO I) 30 (30%) and non keratinized (WHO II) 12 (12%). Table 2.

The relationship between histological types of PNC and cervical lymph nodes involvement were, WHO type III 48 (82.9%), WHO type I 8(26.7%) and WHO type II 6 (50%). Table 3.

**Discussion:**

The first nodal station in NPC is the retropharyngeal node which is not clinically palpable but may be shown on cross-sectional imaging. Early diagnosis hence must precede the cervical lymphadenopathy which remains the most common presentation. Besides the fact that the tumour bed is a lympho-epithelium rich in lymphatics allowing early locoregional spread to one or both sides of the neck.<sup>12</sup>

The relationship between the histological differentiation of the primary tumour and its tendency to metastasize is

not certain. Although it has been suggested that the poorer the differentiation the more likely the tumour is to metastasize.<sup>13</sup> More recently it has been shown that a close relationship exists between certain histopathological features and neck node metastasis.<sup>14</sup> Painless cervical lymph nodes involvement account for 62% in the present study. This is similar to other studies.<sup>12-15,16</sup> However, others reported that cervical lymph nodes involvement occurred in higher percentage 70-90%.<sup>3-17,18</sup> The later studies were carried on an advanced NPC and used other tools for the diagnosis of cervical lymph nodes metastasis like, CT scanning and MRI.

In the present study WHO type III found in 58% and 82.7% of them

presented with cervical lymph nodes affection. This is similar to other studies reported that WHO type III is the most common histopathological type and associated with higher cervical lymph nodes involvement.<sup>10-19,20</sup> In the present study WHO type I found in 30% of NPC, while 26.6% of these cases presented with cervical lymph node involvement. This agreement with other studies mentioned that WHO type I is associated with lower incidence of cervical lymph nodes involvement.<sup>17,18,19,20</sup> Its prognosis is worse because of a higher incidence of death from uncontrolled primary tumours and nodal metastases.<sup>17-19</sup>

WHO type II carcinoma found in this study in 12% and cervical lymph nodes involvement in 50% of them. This agreement with other study reported that WHO type II accounts for 12% of NPC.<sup>21</sup> However, Chan et al.<sup>10</sup> reported that the most NPC in endemic areas is of WHO type II and WHO type III. Corry et al.<sup>19</sup> mentioned that WHO type II account for 6.6% of NPC. This is lower than our results

Generally keratinizing squamous cell carcinoma is relatively radioresistant but less aggressive in behavior. The undifferentiated nasopharyngeal carcinoma is more radiosensitive but aggressive, frequently with advanced

locoregional spread. 12 NPC in low-risk populations is of the poorly differentiated type in contrast to the common well differentiated type in sporadic cases.

### Conclusion:

The nasopharynx is still the most frequent site for an occult primary in the head and neck with cervical metastases. The most histological type of NPC was WHO type III followed by WHO type I cervical lymph nodes involvement were more prevalent with WHO type III and

high incidence was in males in all histological types of NPC.

**Table 1: Relation between histological subtype of NPC and sex of patients.**

WHO classification	No. of patients n=100				
	Males	%	Females	%	Total
WHO type III	42	72.4	16	27.6	58
WHO type II	8	66.3	4	33.7	12
WHO type I	20	66.7	10	33.3	30
TOTAL	70		30		100

**Table 2: Histological type of NPC**

WHO Classification of NPC	No. case	Percentage %
WHO type III	58	58 %
WHO type II	12	12 %
WHO type I	30	30 %

NPC: Nasopharyngeal Carcinoma.

**Table 3: Cervical LN involvement.**

Histological type of NPC	Cervical LN involvement			
	Unilateral	Bilateral	Total	%
WHO type III	30	18	48	82.8
WHO type II	3	3	6	50
WHO type I	4	4	8	26.7

LN : Lymph Nodes

### References:

1. Mcdermott AL, Dutt SN, Watkinson JC The aetiology of nasopharyngeal carcinoma. Clin Oto Laryngol (2001) 26:82-92.

2. Chan SH Aetiology of nasopharyngeal carcinoma. Ann Acad Med Singapore (1990) 19:201-207.
3. Chiesa F, Depaoli F Distant Metastases from nasopharyngeal cancer. ORLJ (2001) 63 (4): 214-6.
4. Oburra HO Late presentation of laryngeal and nasopharyngeal cancer in Kenyatta National Hospital. East Afr Med J (1998) Apr; 75(4):223-6.
5. Leong JL, Fong LW, Low WK Factors contributing to delayed diagnosis in nasopharyngeal carcinoma. J Laryngol Otol (1999) Jul; 113 (7):633-6.
6. Skinner DW, Van Hasselt CA, Tsao SY Nasopharyngeal carcinoma: modes of presentation. Ann Otol Rhinol Laryngol (1991) 100:544-51.
7. Low WK, Leong JL Correlating clinical appearance of nasopharyngeal carcinoma with tumour staging. J R Coll Surg Edinb (2000) 45:146-147.
8. Altum M, Fandi A, Dupuis O, Cvitkov CE, Krajino Z, Eschwege F Undifferentiated nasopharyngeal Cancer Int J Radiat Oncol Biol Phys (1995) 859-877.
9. Frezza G, Barbieri E, Emiliani E, Silvano M, Babini L Patterns of failure in nasopharyngeal cancer treated with megavoltage irradiation. Radiother Oncol (1986) 5:287-294.
10. Chan AT, Teo ML, Lee WY, Kwan WH, Choi PH, Johnson PJ The significance of keratinizing squamous cell histology in Chinese patients with nasopharyngeal carcinoma. Clin Oncol (1998) 10:161-164.
11. He G, Liu S Quality of life and coping styles in Chinese nasopharyngeal cancer patients after hospitalization. Cancer nursing (2005) 28 (3): 179-86.
12. Chuan TC Nasopharynx (The postnasal space). In: Hibbert J, editor. Scott-Brown's Otolaryngology. 6th edition, vol.5. Oxford: Butterworth-Heinemann; P (1997) 5/13/1-30.
13. Holm IE, Lundquist PG, Silfvesvard C, Sobin A Histological grading of Malignancy in squamous cell carcinoma of the oral tongue. Acta Oto Laryngol (1982) 16:52-58.

14. Bryne M, Koppang HS, Lilleng R, Kjaerheim A. Malignancy grading of the deep invasive Margins of oral squamous cell carcinoma has high prognostic value. *J Pathol* (1992)166: 375-381.
15. Uzcudun AE, Fernandez PB, Sanchez JJ, Grande AG, Retolaza IR, Baron MG, et al. Clinical features of pharyngeal cancer: a retrospective study of 258 consecutive patients. *J Laryngol Otol*(2001) 115:112-118.
16. Horsinger FC, Myers JN. Carcinoma of the oral cavity and pharynx. In: Lee KJ, editor. *Essential Otolaryngology Head and Neck surgery*. 8th edition. New York : McGraw- Hill; (2003) P 560-595.
17. Weber AL, Al-arayedh S, Rashid A. Nasopharyngeal; clinical, pathologic, and radiologic assessment. *Neuroimaging Clin North Am*(2003)13(3): 465-83.
18. Lim LH, Goh CH, Long SL, Khin LW, Balakrishnan A, Wee J. Nasopharyngeal carcinoma in young patients. *Int J Clin Pract Dec*; (2003) 57 (10):871-4.
19. Corry J, Fisher R, Rischin D, Porceddu LJ. Clinical verification of the Superiority of the current International Union Against Cancer staging criteria in an Australian Population of patients with nasopharyngeal carcinoma. *Australas Radiol Dec*. (2004) 48 (4):509-15.
20. Neel III HB, Taylor WF, Pearson GR. Prognostic determinants and a view of staging for patients with nasopharyngeal carcinoma. *Ann Otol Rhinol Laryngol*(1985) 94:529-537.
21. Neel III HB. Nasopharyngeal carcinoma. Clinical presentation, diagnosis, treatment and prognosis. *Otolaryngol Clin North Am*(1985) 479-490.
22. Fang B, Forastiere A. Head and Neck cancer. In: Abraham J, Allerga CJ, eds. *Bethesda Handbook of clinical oncology*. Philadelphia: Lippincott Williams & Wilkins; (2001) P3-28.
23. Kasprzycka M, Wierzbicki P, Nowaczyk M, et al. Cellcept enhances the rate of apoptosis in T cells after renal transplantation. *Transplantation Proc* 1999; 31(1-2): 328.
24. Allison AC. Immunosuppressive drugs: the first 50 years and a glance forward. *Immunopharmacology* 2000; 47(2-3): 63-83.
25. Hutchinson P, Steven JC, Robert CA and Holdsworth SR. Laboratory assessment of immune function in renal transplant patients. *Nephrology Dialysis Transplantation* 2003; 18(5): 983-989.